Copaxone Highlights. Teva had a big presence at ECTRIMS, with
a centrally located booth touting a "Think Thin" campaign (lower
gauge needle) and Copaxone's long-term efficacy and safety. Foot
traffic was high, seemingly reflective of physician loyalty. Data-wise,
we were encouraged by SONG trial results, which found a lower
volume dose (20mg in 0.5ml, 1/1/11 PDUFA) effective in reducing
pain and injection site reactions vs. the current 20mg in 1.0ml dose.
Curiously, AEs were higher for the lower volume dose (18.1% vs.
12.5%, with more infections seen), but there were no deaths, SAEs
or AEs that lead to discontinuation.
the above was written in a Jefferies report by Corey Davis
